Pyrazines, pyrimidines and pyridazines useful in the treatment of senile
申请人:Merck Sharp & Dohme Limited
公开号:US05260293A1
公开(公告)日:1993-11-09
The present invention provides pyrazines, pyridazines or pyrimidines, or salts or prodrugs thereof, substituted on one of the ring carbon atoms thereof with a non-aromatic azacyclic or azabicyclic ring system; and independently substituted on each of the other ring carbon atoms with a substituent of low lipophilicity or a hydrocarbon substituent; which compounds stimulate central muscarinic acetylcholine receptors and therefore are useful in the treatment of neurological and mental illnesses.
Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives
作者:Leslie J. Street、Raymond Baker、Tracey Book、Austin J. Reeve、John Saunders、Timothy Willson、Rosemarie S. Marwood、Shailendra Patel、Stephen B. Freedman
DOI:10.1021/jm00080a014
日期:1992.1
been explored. Optimal muscarinic agonist activity was observed for unsubstituted pyrazines in the azanorbornane series. The exo-1-azanorbornane 18a is one of the most efficacious and potent centrally active muscarinic agonists known. Studies on the 3-substituted derivatives have provided evidence of the preferred conformation of these ligands for optimal muscarinicactivity. Substitution at C6 gave
Synthesis of azabicyclic pyrazine derivatives as muscarinic agonists and the preparation of a chloropyrazine analogue with functional selectivity at sub-types of the muscarinic receptor
作者:Raymond Baker、Leslie J. Street、Austin J. Reeve、John Saunders
DOI:10.1039/c39910000760
日期:——
The synthesis of quinuclidine and azanorbornyl pyrazine derivatives has yielded highly potent and efficacious muscarinic agonists; chloro-substitution in the pyrazine ring of the quinuclidine analogue resulted in the formation of a derivative with both enantiomers displaying partial agonist character but, more importantly, functional selectivity at the M1, M2 and M3 sub-types of the muscarinic receptor
Pyrazines, pyrimidines and pyridazines, useful in the treatment of senile dementia
申请人:MERCK SHARP & DOHME LTD.
公开号:EP0327155A2
公开(公告)日:1989-08-09
The present invention provides pyrazines, pyridazines or pyrimidines, or salts or prodrugs thereof, substituted on one of the ring carbon atoms therefore with a non-aromatic azacyclic or azabicyclic ring system; and independently substituted on each of the other ring carbon atoms with a substituent of low lipophilicity or a hydrocarbon substituent; which compounds stimulate central muscarinic acetylcholine receptors and therefore are useful in the treatment of neurological and mental illnesses.